Nathan H. Walcker, MBA, chief executive officer, Florida Cancer Specialists & Research Institute (FCSRI), discusses what guests can expect at the in-person Tampa meeting of The American Journal of Managed Care®'s Institute for Value-Based Medicine® (IVBM), co-hosted by FCSRI.
In-person attendees of the upcoming Institute for Value-Based Medicine® (IVBM) meeting in Tampa, Florida, can expect rich dialogue regarding the state of oncology care today, including physician burnout, advancements in therapeutics, and more, said Nathan H. Walcker, MBA, chief executive officer, Florida Cancer Specialists & Research Institute.
Transcript
What should guests of the upcoming Tampa IVBM meeting look forward to?
First and foremost, I couldn't be more excited to be hosting the event and having a number of our clinical leaders and administrative leaders be participating. Ultimately, what folks can expect when it comes to that is a really rich dialogue around the state of oncology care today and recognizing that we've come a long way over the past 5 years; more specifically, through the COVID-19 pandemic.
Really unpacking a lot of the issues that we all know are out there, but doing so in 1 session, in 1 day. Hearing from folks on physician burnout, looking at great opportunities in clinical trials and advancements in therapeutics. And again, getting together with like-minded stakeholders that are making sure that at the end of the day, it would take a village to provide oncology care. And if we have an opportunity together to learn from one another, what better place to do it than in Tampa. Unfortunately, it's not football season, but there's enough sports to go around and the weather's not too bad either.
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Legal Navigation Services Key to Addressing Disparities in Cancer Care
July 31st 2025A significant number of patients with cancer, caregivers, and health care professionals face significant disparities in legal issues, with the most common needs revolving around health insurance, finances, employment, and disability insurance.
Read More
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More